UF-021 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
90網膜色素変性症3

90. 網膜色素変性症


臨床試験数 : 147 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01786395
(ClinicalTrials.gov)
March 201323/1/2013Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaPhase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration PeriodRetinitis PigmentosaDrug: UF-021;Drug: PlaceboR-Tech Ueno, Ltd.NULLTerminated20 Years70 YearsBoth202Phase 3Japan
2JPRN-JapicCTI-090748
01/10/200820/04/2009Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosaPhase II Study of 0.15% UF-021 in patients with retinitis pigmentosa retinitis pigmentosaIntervention name : UF-021 (isopropyl unoprostone)
Dosage And administration of the intervention : Eye drop
R-Tech Ueno, LtdNULL2065BOTH105Phase 2NULL
3JPRN-JapicCTI-132079
Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration PeriodPhase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period Retinitis PigmentosaIntervention name : UF-021(isopropyl unoprostone)
Dosage And administration of the intervention : Eye drop
Control intervention name : null
R-Tech Ueno, LtdNULL2070BOTHPhase 3NULL